All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

etoricoxib 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
selective cyclo-oxygenase inhibitors	1113	202409-33-4

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: etoricoxib arcoxia etobrix etocox etoxib etropain nucoxia torcoxia MK-0663	A sulfone and pyridine derivative that acts as a cyclooxygenase-2 inhibitor. It is used as a NSAID for the treatment of pain associated with RHEUMATOID ARTHRITIS and ANKYLOSING SPONDYLITIS. It is also used for the short-term treatment of moderate postoperative dental pain. Molecular weight: 358.84 Formula: C18H15ClN2O2S CLOGP: 2.35 LIPINSKI: 0 HAC: 4 HDO: 0 TPSA: 59.92 ALOGS: -5.04 ROTB: 3

Drug dosage:

Dose	Unit	Route
60	mg	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	0.14 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	0.50 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	4.78 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	99 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	1.50 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	0.79 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.08 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	26 hours	Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Property	Description	Value	Unit	Confidence	Similarity
kinase-safety-class	ACVR2B,CDK9,GRK2,PDK1,PDK2,PIK3CG,PRKDC	7
pfas-class	PFAS structural alert (1 = True, 0 = False)	0

Approvals:

Date	Agency	Company	Orphan
Jan. 1, 1998	YEAR INTRODUCED

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug interaction	65.12	15.19	118	10772	276335	90341222
Lung adenocarcinoma stage IV	63.85	15.19	14	10876	436	90617121
Labelled drug-drug interaction medication error	62.75	15.19	32	10858	14550	90603007
Spinal osteoarthritis	54.58	15.19	32	10858	19116	90598441
Fixed eruption	53.71	15.19	16	10874	1714	90615843
Inflammatory marker increased	50.96	15.19	24	10866	9190	90608367
Thrombocytosis	50.67	15.19	22	10868	6979	90610578
Axial spondyloarthritis	48.85	15.19	12	10878	619	90616938
Ophthalmic herpes zoster	46.21	15.19	16	10874	2772	90614785
Cervical dysplasia	43.97	15.19	17	10873	4017	90613540
Adjacent segment degeneration	43.49	15.19	7	10883	36	90617521
Diverticulum intestinal	42.08	15.19	21	10869	9121	90608436
Central pain syndrome	38.31	15.19	10	10880	660	90616897
Apraxia	37.56	15.19	13	10877	2249	90615308
Hyperaesthesia	36.19	15.19	20	10870	10682	90606875
Perseveration	35.67	15.19	8	10882	277	90617280
Disorientation	34.53	15.19	34	10856	44080	90573477
Spinal pain	33.86	15.19	22	10868	15745	90601812
Groin pain	33.73	15.19	20	10870	12193	90605364
Infusion related reaction	33.65	15.19	5	10885	416775	90200782
Junctional ectopic tachycardia	32.05	15.19	7	10883	214	90617343
Drug abuse	31.60	15.19	44	10846	82303	90535254
Porphyrins urine increased	31.52	15.19	5	10885	23	90617534
Chronic gastritis	31.20	15.19	13	10877	3728	90613829
Polymyalgia rheumatica	30.75	15.19	14	10876	4963	90612594
Porphyrins stool increased	30.41	15.19	5	10885	30	90617527
Systemic lupus erythematosus	30.01	15.19	4	10886	361892	90255665
Drug reaction with eosinophilia and systemic symptoms	29.89	15.19	31	10859	42727	90574830
Reactive gastropathy	29.07	15.19	8	10882	646	90616911
Joint contracture	28.99	15.19	10	10880	1712	90615845
Withdrawal syndrome	28.94	15.19	23	10867	22501	90595056
Iliotibial band syndrome	28.28	15.19	7	10883	373	90617184
Foramen magnum stenosis	27.48	15.19	6	10884	183	90617374
Intervertebral disc protrusion	27.14	15.19	24	10866	27172	90590385
Metastases to lymph nodes	26.81	15.19	17	10873	11672	90605885
Meteoropathy	26.56	15.19	4	10886	12	90617545
Rotator cuff syndrome	26.55	15.19	19	10871	15900	90601657
Synovectomy	26.52	15.19	6	10884	216	90617341
Thoracic vertebral fracture	26.46	15.19	13	10877	5461	90612096
Wound	25.97	15.19	3	10887	302977	90314580
Lumbar vertebral fracture	25.39	15.19	14	10876	7444	90610113
Abdominal discomfort	25.15	15.19	13	10877	477315	90140242
Hip deformity	25.07	15.19	6	10884	277	90617280
Ischaemic stroke	25.04	15.19	21	10869	22145	90595412
Product dose omission issue	24.72	15.19	3	10887	291684	90325873
Osteoarthritis	24.68	15.19	65	10825	195665	90421892
Porphyria non-acute	24.67	15.19	6	10884	297	90617260
Femur fracture	24.58	15.19	29	10861	46053	90571504
Diaphragmatic hernia	24.37	15.19	7	10883	660	90616897
Thyroid hormones decreased	24.15	15.19	7	10883	682	90616875
Chondromalacia	24.12	15.19	6	10884	326	90617231
Unwanted pregnancy	24.10	15.19	5	10885	119	90617438
Pustule	23.98	15.19	10	10880	2873	90614684
Nail avulsion	23.77	15.19	6	10884	346	90617211
Cyst	23.64	15.19	18	10872	16543	90601014
Ovulation disorder	23.55	15.19	4	10886	30	90617527
Toxic epidermal necrolysis	23.48	15.19	24	10866	32504	90585053
Osteoporosis postmenopausal	23.43	15.19	6	10884	367	90617190
Vertebral lesion	23.36	15.19	7	10883	765	90616792
Gastrointestinal infection	22.78	15.19	15	10875	10975	90606582
Ankylosing spondylitis	22.65	15.19	16	10874	13117	90604440
Pericarditis	22.36	15.19	3	10887	270148	90347409
Hypotonia	22.25	15.19	15	10875	11411	90606146
Nasal turbinate hypertrophy	22.14	15.19	7	10883	914	90616643
Peripheral nerve lesion	21.96	15.19	6	10884	471	90617086
Drug eruption	21.79	15.19	24	10866	35383	90582174
Diverticulitis	21.76	15.19	27	10863	45160	90572397
Acute kidney injury	21.72	15.19	86	10804	320301	90297256
Pericardial effusion malignant	21.67	15.19	5	10885	197	90617360
Serum ferritin decreased	21.52	15.19	9	10881	2605	90614952
Meniscus injury	21.47	15.19	13	10877	8224	90609333
Postoperative delirium	21.33	15.19	5	10885	211	90617346
Sopor	21.18	15.19	20	10870	24624	90592933
Spinal fracture	21.12	15.19	19	10871	21997	90595560
Angioedema	21.01	15.19	32	10858	64844	90552713
Skin hyperpigmentation	20.98	15.19	12	10878	6839	90610718
Ovarian cyst	20.80	15.19	17	10873	17301	90600256
Radial nerve palsy	20.50	15.19	6	10884	605	90616952
Hyperlipidaemia	20.47	15.19	19	10871	22897	90594660
Hallucination, visual	20.34	15.19	19	10871	23073	90594484
Aortic valve stenosis	20.28	15.19	10	10880	4230	90613327
Paranasal sinus inflammation	20.23	15.19	6	10884	633	90616924
Interspinous osteoarthritis	20.13	15.19	4	10886	76	90617481
Alopecia	20.05	15.19	18	10872	495053	90122504
Synovial disorder	19.99	15.19	9	10881	3109	90614448
Uveitis	19.92	15.19	16	10874	15887	90601670
Sinobronchitis	19.68	15.19	6	10884	695	90616862
Tumour invasion	19.57	15.19	5	10885	303	90617254
Supraventricular tachycardia	19.54	15.19	16	10874	16320	90601237
Lactic acidosis	19.41	15.19	27	10863	50436	90567121
Excessive eye blinking	19.41	15.19	7	10883	1365	90616192
Dysplasia	19.30	15.19	7	10883	1387	90616170
Dyschromatopsia	19.23	15.19	6	10884	751	90616806
Sensation of foreign body	19.09	15.19	11	10879	6355	90611202
Vocal cord leukoplakia	19.06	15.19	3	10887	13	90617544
Patellofemoral pain syndrome	19.05	15.19	6	10884	774	90616783
Pyelocaliectasis	18.98	15.19	6	10884	783	90616774
Mesenteritis	18.98	15.19	5	10885	342	90617215
Subileus	18.65	15.19	9	10881	3635	90613922
Hyperreflexia	18.64	15.19	11	10879	6646	90610911
Dysaesthesia	18.26	15.19	10	10880	5245	90612312
Blood iron decreased	18.22	15.19	16	10874	17943	90599614
Sudden death	18.14	15.19	13	10877	10896	90606661
Carotid artery stenosis	18.12	15.19	10	10880	5324	90612233
Hepatitis A antibody abnormal	18.11	15.19	4	10886	129	90617428
Dermatitis psoriasiform	18.05	15.19	8	10882	2664	90614893
Defaecation disorder	18.02	15.19	6	10884	923	90616634
Facial paresis	17.93	15.19	9	10881	3954	90613603
Disturbance in attention	17.81	15.19	25	10865	47084	90570473
Product prescribing error	17.81	15.19	20	10870	30125	90587432
Allodynia	17.45	15.19	6	10884	1018	90616539
Hepatic enzyme increased	17.31	15.19	11	10879	360725	90256832
Nasal septum deviation	17.04	15.19	7	10883	1936	90615621
Speech disorder	16.95	15.19	24	10866	45561	90571996
Ulnar nerve injury	16.75	15.19	4	10886	183	90617374
Osteopenia	16.66	15.19	17	10873	22985	90594572
Hemianopia	16.57	15.19	7	10883	2075	90615482
Respiratory tract infection	16.19	15.19	27	10863	59051	90558506
Tendon disorder	16.00	15.19	10	10880	6690	90610867
Epidermal necrosis	15.73	15.19	7	10883	2354	90615203
Infected fistula	15.60	15.19	4	10886	246	90617311
Collagen disorder	15.46	15.19	4	10886	255	90617302
Acquired porphyria	15.45	15.19	5	10885	704	90616853
Bone marrow oedema	15.36	15.19	6	10884	1457	90616100
Substance abuse	15.31	15.19	9	10881	5397	90612160
Joint swelling	15.31	15.19	23	10867	503277	90114280
Eosinophilia	15.29	15.19	18	10872	28515	90589042
Hiatus hernia	15.28	15.19	17	10873	25344	90592213
Anaemia	15.23	15.19	83	10807	352719	90264838
Pneumonia haemophilus	15.20	15.19	6	10884	1497	90616060

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Regurgitation	66.50	17.29	21	7257	1919	42612138
General physical health deterioration	62.95	17.29	101	7177	151145	42462912
Spinal pain	49.95	17.29	24	7254	6758	42607299
Systemic infection	49.52	17.29	22	7256	5183	42608874
Hepatitis E antibody positive	49.40	17.29	11	7267	256	42613801
Pregnancy of partner	49.10	17.29	12	7266	423	42613634
Body mass index abnormal	48.17	17.29	10	7268	165	42613892
Hepatitis E virus test positive	47.83	17.29	11	7267	297	42613760
Oropharyngeal discomfort	47.54	17.29	20	7258	4129	42609928
Vitamin B12 deficiency	47.45	17.29	21	7257	4901	42609156
Death	44.08	17.29	13	7265	471172	42142885
Bursitis	42.68	17.29	21	7257	6223	42607834
Oral mucosa erosion	42.45	17.29	13	7265	1073	42612984
Eructation	42.18	17.29	20	7258	5466	42608591
Mucosal necrosis	41.54	17.29	8	7270	88	42613969
Antiphospholipid antibodies positive	39.84	17.29	10	7268	394	42613663
Ligament calcification	39.54	17.29	9	7269	232	42613825
Axial spondyloarthritis	36.87	17.29	10	7268	535	42613522
Product prescribing error	35.58	17.29	32	7246	26080	42587977
Neck pain	35.52	17.29	34	7244	29980	42584077
Suspected transmission of an infectious agent via product	35.51	17.29	11	7267	943	42613114
Coating in mouth	35.13	17.29	7	7271	93	42613964
Lip erosion	35.13	17.29	10	7268	640	42613417
Ankylosing spondylitis	34.63	17.29	19	7259	7037	42607020
Respiratory fatigue	33.86	17.29	7	7271	113	42613944
Hand fracture	33.27	17.29	14	7264	2892	42611165
Electric shock sensation	33.23	17.29	9	7269	479	42613578
Chronic idiopathic pain syndrome	32.21	17.29	7	7271	145	42613912
Sacroiliitis	31.17	17.29	12	7266	1970	42612087
Prostatic pain	31.04	17.29	8	7270	351	42613706
Craniocerebral injury	29.54	17.29	14	7264	3820	42610237
Palmoplantar pustulosis	28.49	17.29	8	7270	487	42613570
Adjustment disorder with disturbance of conduct	27.95	17.29	6	7272	117	42613940
Helicobacter gastritis	27.89	17.29	10	7268	1347	42612710
Osteoarthritis	27.65	17.29	27	7251	24378	42589679
Fluid intake reduced	25.90	17.29	13	7265	4019	42610038
Otitis media	24.02	17.29	12	7266	3671	42610386
Costovertebral angle tenderness	24.00	17.29	5	7273	84	42613973
Haemophilic arthropathy	23.53	17.29	6	7272	252	42613805
Iridocyclitis	23.15	17.29	10	7268	2201	42611856
Paternal exposure during pregnancy	22.55	17.29	5	7273	114	42613943
Poor peripheral circulation	22.35	17.29	9	7269	1662	42612395
Peritoneal adhesions	22.31	17.29	5	7273	120	42613937
Depersonalisation/derealisation disorder	21.89	17.29	7	7271	665	42613392
Gastrointestinal inflammation	21.53	17.29	12	7266	4580	42609477
Formication	20.62	17.29	9	7269	2032	42612025
Psoriatic arthropathy	20.05	17.29	23	7255	24944	42589113
Pharyngeal exudate	19.73	17.29	3	7275	6	42614051
Pharyngeal lesion	19.73	17.29	3	7275	6	42614051
Febrile neutropenia	19.48	17.29	4	7274	185699	42428358
pH body fluid increased	19.32	17.29	4	7274	65	42613992
Immune-mediated adverse reaction	19.25	17.29	7	7271	981	42613076
Oral pruritus	19.21	17.29	6	7272	528	42613529
Anaemia of malignant disease	19.14	17.29	6	7272	535	42613522
Prerenal failure	19.10	17.29	9	7269	2424	42611633
Personality change	19.09	17.29	12	7266	5707	42608350
Cardiac valve sclerosis	19.04	17.29	4	7274	70	42613987
Sialadenosis	18.87	17.29	3	7275	9	42614048
Open angle glaucoma	18.41	17.29	5	7273	269	42613788
Polyneuropathy	18.13	17.29	19	7259	18642	42595415
Impaired healing	17.72	17.29	18	7260	17035	42597022
Drug interaction	17.63	17.29	91	7187	266908	42347149
Aortic valve incompetence	17.61	17.29	12	7266	6536	42607521
Intensive care unit acquired weakness	17.50	17.29	7	7271	1271	42612786
Endocarditis	17.45	17.29	13	7265	8139	42605918
Condition aggravated	17.30	17.29	89	7189	260665	42353392

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug interaction	81.22	14.19	203	15566	499980	110073550
Regurgitation	69.57	14.19	24	15745	3461	110570069
Product prescribing error	57.34	14.19	52	15717	51279	110522251
Spinal pain	55.56	14.19	34	15735	18481	110555049
Fixed eruption	54.16	14.19	21	15748	4211	110569319
Axial spondyloarthritis	52.17	14.19	14	15755	864	110572666
Hepatitis E antibody positive	51.29	14.19	11	15758	258	110573272
Labelled drug-drug interaction medication error	50.11	14.19	38	15731	29264	110544266
Thrombocytosis	49.86	14.19	26	15743	10418	110563112
Hepatitis E virus test positive	49.80	14.19	11	15758	297	110573233
Oral mucosa erosion	49.42	14.19	17	15752	2431	110571099
Inflammatory marker increased	47.11	14.19	28	15741	14441	110559089
Lip erosion	45.75	14.19	15	15754	1851	110571679
Ankylosing spondylitis	45.14	14.19	28	15741	15584	110557946
Pregnancy of partner	44.20	14.19	10	15759	302	110573228
Lung adenocarcinoma stage IV	43.05	14.19	11	15758	560	110572970
Ligament calcification	41.11	14.19	9	15760	233	110573297
Perseveration	41.08	14.19	10	15759	417	110573113
General physical health deterioration	40.53	14.19	143	15626	425152	110148378
Systemic infection	40.01	14.19	22	15747	9797	110563733
Thoracic vertebral fracture	38.90	14.19	19	15750	6636	110566894
Toxic epidermal necrolysis	38.65	14.19	44	15725	56683	110516847
Polymyalgia rheumatica	36.48	14.19	18	15751	6424	110567106
Mucosal necrosis	36.47	14.19	8	15761	209	110573321
Chronic gastritis	36.35	14.19	17	15752	5394	110568136
Product dose omission issue	34.76	14.19	3	15766	321779	110251751
Central pain syndrome	34.61	14.19	10	15759	810	110572720
Vitamin B12 deficiency	34.15	14.19	20	15749	10035	110563495
Skin hyperpigmentation	34.11	14.19	19	15750	8677	110564853
Coating in mouth	34.00	14.19	8	15761	288	110573242
Prostatic pain	33.92	14.19	8	15761	291	110573239
Death	33.79	14.19	30	15739	698839	109874691
Oropharyngeal discomfort	33.66	14.19	20	15749	10307	110563223
Body mass index abnormal	33.39	14.19	10	15759	918	110572612
Suspected transmission of an infectious agent via product	33.31	14.19	11	15758	1389	110572141
Infusion related reaction	33.08	14.19	7	15762	381155	110192375
Femur fracture	32.88	14.19	36	15733	44433	110529097
Sacroiliitis	31.48	14.19	15	15754	4963	110568567
Immune-mediated adverse reaction	31.21	14.19	11	15758	1689	110571841
Intervertebral disc protrusion	30.81	14.19	28	15741	27670	110545860
Lumbar vertebral fracture	30.59	14.19	18	15751	9113	110564417
Chronic idiopathic pain syndrome	30.52	14.19	7	15762	225	110573305
Spinal osteoarthritis	29.80	14.19	24	15745	20159	110553371
Porphyrins urine increased	29.70	14.19	5	15764	29	110573501
Synovectomy	29.54	14.19	7	15762	260	110573270
Antiphospholipid antibodies positive	29.07	14.19	9	15760	924	110572606
Respiratory fatigue	28.77	14.19	7	15762	291	110573239
Eructation	28.02	14.19	20	15749	14037	110559493
Porphyrins stool increased	27.87	14.19	5	15764	44	110573486
Withdrawal syndrome	27.84	14.19	28	15741	31352	110542178
Poor peripheral circulation	27.62	14.19	13	15756	4184	110569346
Iridocyclitis	27.36	14.19	14	15755	5394	110568136
Hyperaesthesia	27.19	14.19	20	15749	14707	110558823
Anaemia	26.91	14.19	151	15618	546935	110026595
Helicobacter gastritis	26.60	14.19	11	15758	2605	110570925
Apraxia	26.53	14.19	12	15757	3528	110570002
Craniocerebral injury	26.14	14.19	14	15755	5920	110567610
Meteoropathy	25.88	14.19	4	15765	12	110573518
Systemic lupus erythematosus	25.83	14.19	3	15766	254335	110319195
Haemophilic arthropathy	25.64	14.19	6	15763	211	110573319
Palmoplantar pustulosis	24.47	14.19	8	15761	978	110572552
Drug eruption	24.38	14.19	34	15735	53625	110519905
Tongue oedema	24.36	14.19	15	15754	8241	110565289
Sopor	24.31	14.19	28	15741	36518	110537012
Disorientation	23.88	14.19	39	15730	70632	110502898
Diaphragmatic hernia	23.75	14.19	7	15762	608	110572922
Joint contracture	23.74	14.19	10	15759	2481	110571049
Spinal fracture	23.47	14.19	22	15747	22611	110550919
Dermatitis psoriasiform	23.10	14.19	11	15758	3633	110569897
Thyroid hormones decreased	22.90	14.19	7	15762	688	110572842
Electric shock sensation	22.60	14.19	9	15760	1935	110571595
Fluid intake reduced	21.40	14.19	13	15756	6973	110566557
Pericarditis	21.24	14.19	3	15766	219111	110354419
Wound	20.96	14.19	4	15765	234433	110339097
Gamma-glutamyltransferase increased	20.94	14.19	34	15735	61275	110512255
Pustule	20.47	14.19	10	15759	3494	110570036
Abdominal discomfort	20.12	14.19	16	15753	393842	110179688
Ischaemic stroke	20.04	14.19	27	15742	41236	110532294
Dysuria	20.03	14.19	33	15736	60198	110513332
Completed suicide	19.92	14.19	5	15764	242376	110331154
Neck pain	19.92	14.19	50	15719	123080	110450450
Open angle glaucoma	19.85	14.19	6	15763	568	110572962
Costovertebral angle tenderness	19.71	14.19	5	15764	247	110573283
Hand fracture	19.60	14.19	13	15756	8109	110565421
Maternal exposure during pregnancy	19.57	14.19	6	15763	254877	110318653
pH body fluid increased	19.55	14.19	4	15765	74	110573456
Interspinous osteoarthritis	19.45	14.19	4	15765	76	110573454
Electrolyte imbalance	19.17	14.19	25	15744	37003	110536527
Synovial disorder	18.83	14.19	9	15760	2998	110570532
Pharyngeal exudate	18.74	14.19	3	15766	12	110573518
Intentional product use issue	18.74	14.19	6	15763	247900	110325630
Off label use	18.40	14.19	132	15637	1500053	109073477
Porphyria non-acute	18.22	14.19	6	15763	751	110572779
Cardiac valve sclerosis	18.15	14.19	4	15765	107	110573423
Skin lesion	18.14	14.19	29	15740	51602	110521928
Otitis media	18.12	14.19	12	15757	7464	110566066
Peritoneal adhesions	18.07	14.19	5	15764	346	110573184
Oral pruritus	17.98	14.19	9	15760	3311	110570219
Face oedema	17.95	14.19	23	15746	33446	110540084
Hyperreflexia	17.78	14.19	13	15756	9472	110564058
Hepatitis A antibody abnormal	17.43	14.19	4	15765	129	110573401
Aortic valve stenosis	17.38	14.19	11	15758	6339	110567191
Toothache	17.28	14.19	19	15750	23556	110549974
Gastrointestinal submucosal tumour	17.28	14.19	4	15765	134	110573396
Prostate cancer metastatic	17.23	14.19	10	15759	4933	110568597
Drug abuse	17.16	14.19	60	15709	177351	110396179
Angioedema	16.99	14.19	41	15728	98459	110475071
Spondylolisthesis	16.84	14.19	9	15760	3789	110569741
Anaemia of malignant disease	16.60	14.19	6	15763	990	110572540
Pharyngeal lesion	16.57	14.19	3	15766	28	110573502
Hemianopia	16.20	14.19	8	15761	2860	110570670
Excessive eye blinking	16.14	14.19	7	15762	1863	110571667
Epidermal necrosis	15.73	14.19	8	15761	3042	110570488
Lip oedema	15.58	14.19	11	15758	7589	110565941
Gastrointestinal inflammation	15.57	14.19	12	15757	9457	110564073
Pneumonitis	15.57	14.19	34	15735	76497	110497033
Urethral stenosis	15.50	14.19	6	15763	1198	110572332
Prerenal failure	15.49	14.19	9	15760	4450	110569080
Lactic acidosis	15.34	14.19	38	15731	92773	110480757
Arthralgia	15.25	14.19	174	15595	779458	109794072
Depersonalisation/derealisation disorder	15.11	14.19	7	15762	2174	110571356
Dyschromatopsia	15.08	14.19	6	15763	1288	110572242
Disease progression	15.06	14.19	8	15761	244026	110329504
Weight increased	14.89	14.19	23	15746	419621	110153909
Subileus	14.80	14.19	10	15759	6427	110567103
Intensive care unit acquired weakness	14.59	14.19	7	15762	2352	110571178
Mucosal ulceration	14.53	14.19	7	15762	2372	110571158
Psychotic behaviour	14.52	14.19	6	15763	1419	110572111
Acquired porphyria	14.50	14.19	5	15764	720	110572810
Parapsoriasis	14.47	14.19	4	15765	276	110573254
Delayed sleep phase	14.40	14.19	3	15766	61	110573469
Ulnar nerve injury	14.25	14.19	4	15765	292	110573238
Gastrointestinal ulcer perforation	14.21	14.19	3	15766	65	110573465
Tuberculosis	14.21	14.19	15	15754	17759	110555771

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	M01AH05	MUSCULO-SKELETAL SYSTEM ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS Coxibs
MeSH PA	D000700	Analgesics
MeSH PA	D000893	Anti-Inflammatory Agents
MeSH PA	D000894	Anti-Inflammatory Agents, Non-Steroidal
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D016861	Cyclooxygenase Inhibitors
MeSH PA	D018501	Antirheumatic Agents
MeSH PA	D018689	Sensory System Agents
MeSH PA	D018712	Analgesics, Non-Narcotic
MeSH PA	D052246	Cyclooxygenase 2 Inhibitors
CHEBI has role	CHEBI:33231	antitubercular agent
CHEBI has role	CHEBI:35475	non-steroidal anti-inflammatory drug
CHEBI has role	CHEBI:35480	analgesic
CHEBI has role	CHEBI:35610	antineoplastic agent
CHEBI has role	CHEBI:35842	antirheumatic drug
CHEBI has role	CHEBI:50629	cyclooxygenase 2 inhibitor
CHEBI has role	CHEBI:64946	anti-HIV agent
CHEBI has role	CHEBI:67079	anti-inflammatory agent
CHEBI has role	CHEBI:73336	vulnerary

Related Drugs by ATC class:

M01AH Coxibs 6 drugs

celecoxiblumiracoxibparecoxibpolmacoxibrofecoxibvaldecoxib

Drug Use | Suggest Off label Use Form| |View source of the data|

None

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	4.6	Basic
pKa2	1.75	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Prostaglandin G/H synthase 2	Enzyme	P35354	PGH2_HUMAN	INHIBITOR	IC50	6.10		WOMBAT-PK	IUPHAR
Prostaglandin G/H synthase 1	Enzyme	P23219	PGH1_HUMAN		IC50	4.92		CHEMBL
Prostaglandin E2 receptor EP2 subtype	GPCR	P43116	PE2R2_HUMAN		Ki	7.10		PDSP
Mitogen-activated protein kinase 14	Kinase	Q16539	MK14_HUMAN		IC50	6.28		CHEMBL
Prostaglandin G/H synthase 2	Enzyme		PGH2_SHEEP		IC50	6.64		CHEMBL

External reference:

ID	Source
D03710	KEGG_DRUG
C0972314	UMLSCUI
CHEBI:6339	CHEBI
CHEMBL416146	ChEMBL_ID
DB01628	DRUGBANK_ID
D000077613	MESH_DESCRIPTOR_UI
123619	PUBCHEM_CID
2896	IUPHAR_LIGAND_ID
8082	INN_ID
WRX4NFY03R	UNII
307296	RXNORM
009633	NDDF
395292007	SNOMEDCT_US
409134009	SNOMEDCT_US
5CH	PDB_CHEM_ID

Pharmaceutical products:

None